Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) has partnered with USA Track & Field (USATF) to implement rapid COVID-19 testing for athletes at the Journey to Gold events. Utilizing the BD Veritor™ Plus system, tests will be administered to ensure athlete safety as they prepare for the U.S. Olympic Trials. The testing program includes administering tests every two days, exceeding U.S. Olympic Committee guidelines. To date, 410 tests have been conducted with two positive results. This initiative aligns with BD's commitment to supporting safe return to competition and community health.
Summary not available.
BD (Becton, Dickinson and Company) is voluntarily recalling specific lots of the ChloraPrep™ Hi-Lite Orange™ 26 mL Applicator due to a manufacturing defect that can lead to broken glass and solution release. The recall affects products distributed in the United States and Puerto Rico. While no severe injuries have been reported, potential risks include superficial to deep lacerations and possible infection. BD has received 56 complaints, with one incident of laceration. The company is notifying affected customers and providing disposal instructions.
BD (Becton, Dickinson and Company) has announced a commitment of $1 million over five years to support UNICEF USA's initiatives targeting the elimination of Maternal and Neonatal Tetanus (MNT) in at-risk countries. This donation builds on BD's ongoing partnership, contributing over $10.8 million to UNICEF's efforts since 1997. The initiative aims to vaccinate women and promote safe childbirth practices, addressing a disease that claims a newborn every 21 minutes. BD continues to advocate for healthcare access among vulnerable populations.
Vicarious Surgical Inc. and D8 Holdings Corp. have reached a definitive business combination agreement, transitioning Vicarious to publicly trade under the new ticker symbol RBOT post-closing on the NYSE. This merger aims to enhance surgical efficiency and patient outcomes through Vicarious's advanced robotics technology, which provides significant cost savings compared to legacy systems. The transaction could yield up to $460 million in gross proceeds, supported by a $115 million private placement. The merger is anticipated to finalize by Q3 2021, pending D8 shareholder approval.
BD (Becton, Dickinson and Company) announced it has received 510(k) clearance from the FDA for its new Pristine™ Long-Term Hemodialysis Catheter, set to be available in the U.S. in May 2021. This innovative catheter features a unique side-hole free symmetric Y-Tip™ distal lumen design aimed at improving patient outcomes by minimizing complications such as thrombus formation. Following a feasibility study involving 45 patients, primary patency rates were reported at 100.0% at 60 days and 90.9% at 180 days, indicating promising performance for patients requiring hemodialysis.
On April 13, 2021, BD (NYSE: BDX) announced that its BD MAX™ Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay has been recognized by the WHO as part of the moderate complexity automated NAAT class for TB diagnostics. This assay allows simultaneous detection of the TB bacteria and mutations for resistance to isoniazid (INH) and rifampicin (RIF). BD emphasizes its commitment to combating antimicrobial resistance and improving TB treatment, marking a significant milestone for the product. The BD MAX™ system is already CE marked and available in Europe and beyond.
BD (Becton, Dickinson and Company) (NYSE: BDX) will announce its financial results for Q2 of fiscal year 2021 on May 6, 2021, at approximately 6:00 a.m. ET. The results will be shared via a press release and presentation materials on its investors' website. Following this, a conference call will be held at 8:00 a.m. ET, and can be accessed through a dedicated telephone line. The webcast will be available for replay until May 13, 2021.
BD (Becton, Dickinson and Company) is set to invest $65 million in a new 120,000 square-foot facility in Tucson, Arizona, aimed at enhancing its supply chain capabilities. The facility will serve as a final-stage manufacturing and sterilization center, expected to be operational by mid-2022, and create approximately 40 new jobs. BD's initiative is projected to generate a $122 million economic impact over the next decade, reinforcing the company's commitment to public health and operational efficiency.
On April 1, 2021, BD (Becton, Dickinson and Company) announced that the FDA granted Emergency Use Authorization (EUA) for its rapid antigen test, the BD Veritor™ Plus System, to screen asymptomatic individuals for SARS-CoV-2 through serial testing. This authorization allows testing twice over two to three days, enhancing the detection of COVID-19 and supporting efforts to return to normalcy. The system facilitates testing in various settings like schools and workplaces, addressing public health reporting challenges through a collaboration with ImageMover for efficient data management.